Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06442579
Other study ID # ONZ-2024-0089
Secondary ID 11PEU24N
Status Recruiting
Phase
First received
Last updated
Start date June 15, 2024
Est. completion date September 30, 2026

Study information

Verified date June 2024
Source University Hospital, Ghent
Contact Arne Defour, Msc.
Phone 09 332 12 43
Email Arne.Defour@UGent.be
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The upper limbs play an essential role for safe and efficient walking in healthy persons and persons post-stroke. Nevertheless, in current post-stroke gait rehabilitation (research) the upper limbs are barely targeted. To address this gap, my project aims to investigate the selective motor control of the upper limbs during walking and the contribution of the cortical activity to the arm swing in independent walkers after stroke. To gain insight in the direct effects of stroke on the arm swing, the primary motor control of the arm swing will be evaluated by determining muscle synergies (i.e group of muscles working together as a task-specific functional unit). Additionally, the cortical activity (EEG-analysis) during walking of persons post-stroke will be compared to healthy controls and the relationship between stroke-induced changes in cortical activity and arm swing deviations will be assessed. Furthermore, I will evaluate whether improvements in cortical activity relate to improvements in primary motor control of the arm swing. This innovative project will be the first to investigate the direct coupling between the cortex and the muscle synergies in persons post-stroke during independent walking to investigate the arm swing. These fundamental insights in the primary motor control of the arm swing and the contribution of the cortical activity will allow to develop targeted interventions aiming to improve arm swing and as such optimize post-stroke gait rehabilitation. Research questions: 1. How can muscle synergies explain arm swing alterations in independent walkers after stroke? 2. How do stroke-induced changes in cortical activity relate to arm swing deviations in persons after stroke? 3. Are changes in primary motor control of the upper limb during walking related to normalization of brain activity in independent walkers after stroke?


Recruitment information / eligibility

Status Recruiting
Enrollment 84
Est. completion date September 30, 2026
Est. primary completion date June 30, 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Stroke Inclusion Criteria: - First-ever, ischemic and cerebral stroke - Maximum one-year post-stroke - Able to walk at least 10 minutes (FAC = 3) - Presence of upper limb paresis (NIHSS item 5a/b > 0) Exclusion Criteria: - Other neurological disorders Healthy controls Inclusion criteria: - Older than 18 years - Able to walk at least 10 minutes Exlusion criteria: - Pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Walking on a treadmill
Participants have to walk without holding handrails and without bodyweight support for at least 200 gait cycles. They are asked to walk at comfortable walking speed while watching forward to a screen without virtual reality projection. Arm should be next to the body to allow arm swing if possible.

Locations

Country Name City State
Belgium Ghent University Hospital Ghent Oost-Vlaanderen

Sponsors (4)

Lead Sponsor Collaborator
University Hospital, Ghent University Ghent, Vrije Universiteit Brussel, VU University of Amsterdam

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Other National Institutes of Health Stroke Scale (NIHSS) Quantifies the impairment caused by a stroke. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The highest score is 42. Single point of assessment at inclusion (only for stroke survivors)
Other National Institutes of Health Stroke Scale (NIHSS) Quantifies the general impairment caused by a stroke after a follow-up period of three months. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The highest score is 42. Single point of assessment 3 months after inclusion (only for stroke survivors)
Other Fugl-Meyer assesment - Upper limbs Assesses specifc motor impairments of the upper limbs of stroke survivors. The Fugl-Meyer Assessment scale is an ordinal scale that has 3 points for each item. A zero score is given for the item if the subject cannot do the task. A score of 1 is given when the task is performed partially and a score of 2 is given when the task is performed fully. However, reflex activity is measured using 2 points only, with a score of 0 or 2 for absence and presence of reflex respectively. Single point of assessment at inclusion (only for stroke survivors)
Other Fugl-Meyer assesment - Upper limbs Assesses specifc motor impairments of the upper limbs of stroke survivors after a follow-up period of three months. The Fugl-Meyer Assessment scale is an ordinal scale that has 3 points for each item. A zero score is given for the item if the subject cannot do the task. A score of 1 is given when the task is performed partially and a score of 2 is given when the task is performed fully. However, reflex activity is measured using 2 points only, with a score of 0 or 2 for absence and presence of reflex respectively. Single point of assessment 3 months after inclusion (only for stroke survivors)
Other Tardieu scale Quantifies spasticity by assessing the muscle's response (0-5) to different stretch velocities (V1, V2 or V3) and by determining the spasticity angle (R1 or R2). Single point of assessment at inclusion (only for stroke survivors)
Other Tardieu scale Quantifies spasticity by assessing the muscle's response (0-5) to different stretch velocities (V1, V2 or V3) and by determining the spasticity angle (R1 or R2). Single point of assessment 3 months after inclusion (only for stroke survivors)
Other 10 Meter Walking Test Examins the walking capacity of a stroke survivor by measuring how long it takes to walk a distance of 10 meters (in seconds). Single point of assessment at inclusion (only for stroke survivors)
Other 10 Meter Walking Test Examins the walking capacity of a stroke survivor by measuring how long it takes to walk a distance of 10 meters (in seconds). Single point of assessment 3 months after inclusion (only for stroke survivors)
Other Fugl-Meyer assesment - Lower limbs Assesses specifc motor impairments of the lower limbs of stroke survivors. The Fugl-Meyer Assessment scale is an ordinal scale that has 3 points for each item. A zero score is given for the item if the subject cannot do the task. A score of 1 is given when the task is performed partially and a score of 2 is given when the task is performed fully. However, reflex activity is measured using 2 points only, with a score of 0 or 2 for absence and presence of reflex respectively. Single point of assessment at inclusion (only for stroke survivors)
Other Fugl-Meyer assesment - Lower limbs Assesses specifc motor impairments of the lower limbs of stroke survivors after a follow-up period of three months. The Fugl-Meyer Assessment scale is an ordinal scale that has 3 points for each item. A zero score is given for the item if the subject cannot do the task. A score of 1 is given when the task is performed partially and a score of 2 is given when the task is performed fully. However, reflex activity is measured using 2 points only, with a score of 0 or 2 for absence and presence of reflex respectively. Single point of assessment 3 months after inclusion (only for stroke survivors)
Primary Number of muscle synergies The number of muscle synergies needed to account for 90% variance in muscle activity measured by surface EMG during walking in stroke survivors compared to healthy controls. Following muscles will be examined:
tibialis anterior,
gastrocnemius lateralis
soleus
vastus medialis
vastus lateralis
rectus femoris
biceps femoris
gluteus medius
erector spinae
latissimus dorsi
anterior deltoid
posterior deltoid
biceps brachii
triceps brachii
Single point of assessment at inclusion
Primary Number of muscle synergies The number of muscle synergies needed to account for 90% variance in muscle activity measured by surface EMG during walking in stroke survivors after a follow-up period of three months. Following muscles will be examined:
tibialis anterior,
gastrocnemius lateralis
soleus
vastus medialis
vastus lateralis
rectus femoris
biceps femoris
gluteus medius
erector spinae
latissimus dorsi
anterior deltoid
posterior deltoid
biceps brachii
triceps brachii
Single point of assessment 3 months after inclusion (only for stroke survivors)
Primary Weight of muscle synergies The number or distribution of muscle weightings within a synergy during walking in stroke survivors compared to healthy controls.
The distribution of muscle activation averages over one gait cycle measured by surface EMG of following muscles:
tibialis anterior,
gastrocnemius lateralis
soleus
vastus medialis
vastus lateralis
rectus femoris
biceps femoris
gluteus medius
erector spinae
latissimus dorsi
anterior deltoid
posterior deltoid
biceps brachii
triceps brachii
Single point of assessment at inclusion
Primary Weight of muscle synergies The number or distribution of muscle weightings within a synergy during walking in stroke survivors after a follow-up period of three months.
The distribution of muscle activation averages over one gait cycle measured by surface EMG of following muscles:
tibialis anterior,
gastrocnemius lateralis
soleus
vastus medialis
vastus lateralis
rectus femoris
biceps femoris
gluteus medius
erector spinae
latissimus dorsi
anterior deltoid
posterior deltoid
biceps brachii
triceps brachii
Single point of assessment 3 months after inclusion (only for stroke survivors)
Primary Brain symmetry index (BSI) The amount of cortical lateralization during walking in stroke survivors compared to healthy controls. The score ranges from -1 to +1 with BSI = 0 reprenting perfect symmetry. Positive values represent higher power in the right hemishere compared to the left hemisphere, vice versa for negative values. For left side lesions, BSI was multiplied by -1. Single point of assessment at inclusion
Primary Brain symmetry index (BSI) The amount of cortical lateralization during walking in stroke survivors after a follow-up period of three months. The score ranges from -1 to +1 with BSI = 0 reprenting perfect symmetry. Positive values represent higher power in the right hemishere compared to the left hemisphere, vice versa for negative values. For left side lesions, BSI was multiplied by -1. Single point of assessment 3 months after inclusion (only for stroke survivors)
Secondary Upper limb kinematics Movements of the upper limb during walking measured by 3D kinematics and expressed as angles (°) Single point of assessment at inclusion
Secondary Upper limb kinematics Movements of the upper limb during walking measured by 3D kinematics and expressed as angles (°) Single point of assessment 3 months after inclusion (only for stroke survivors)
Secondary Cortico-synergy coherence The amount of coherence (i.e. phase locking) between the muscle synergies and cortical activity during walking in stroke survivors compared to healthy controls. Higher values (0-1) indicate a better linear association. Single point of assessment at inclusion
Secondary Cortico-synergy coherence The amount of coherence (i.e phase locking) between the muscle synergies and cortical activity during walking in stroke survivors after a follow-up period of three months. Higher values (0-1) indicate a better linear association. Single point of assessment 3 months after inclusion (only for stroke survivors)
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1